Interaction of Pyk2 and PTP-PEST with leupaxin in prostate cancer cells

American Journal of Physiology - Cell Physiology

Volumn 292, Issue 6, 2007, Pages

  Sahu, Surasri Nandan ^a   Nunez, Stephanie ^b   Bai, Guang ^a   Gupta, Anandarup ^a  

^a UNIVERSITY OF MARYLAND DENTAL SCHOOL   (United States)

^b UNIVERSITY OF MARYLAND BALTIMORE COUNTY   (United States)

Author keywords

c Src; Migration; PC 3; Protein tyrosine phosphatase proline , glutamate , serine , and threonine rich sequence

Indexed keywords

4 (1 AMINOETHYL) N (4 PYRIDYL)CYCLOHEXANECARBOXAMIDE; ADENOVIRUS VECTOR; FOCAL ADHESION KINASE 2; LEUPAXIN; PAXILLIN; PROTEIN TYROSINE PHOSPHATASE; RHO GUANINE NUCLEOTIDE BINDING PROTEIN; UNCLASSIFIED DRUG;

ANIMAL CELL; ARTICLE; CANCER CELL; CANCER CELL CULTURE; CELL ASSAY; EMBRYO; ENZYME ACTIVITY; GENE CONTROL; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; IN VITRO STUDY; MALE; METASTASIS; MOUSE; NONHUMAN; ONCOGENE SRC; PRIORITY JOURNAL; PROSTATE CANCER; PROTEIN PROTEIN INTERACTION; REGULATORY MECHANISM; VIRUS RECOMBINANT;

CELL ADHESION MOLECULES; CELL LINE, TUMOR; CELL MOVEMENT; FOCAL ADHESION KINASE 2; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; MALE; PHOSPHOPROTEINS; PROSTATIC NEOPLASMS; PROTEIN BINDING; PROTEIN-TYROSINE KINASES; PROTEIN-TYROSINE-PHOSPHATASE; PROTO-ONCOGENE PROTEINS; RNA, SMALL INTERFERING; SIGNAL TRANSDUCTION;

EID: 34447529493     PISSN: 03636143     EISSN: 15221563     Source Type: Journal    
DOI: 10.1152/ajpcell.00503.2006     Document Type: Article

References (82)

1. Abe K, Rossman KL, Liu B, Ritola KD, Chiang D, Campbell SL, Burridge K, Der CJ. Vav2 is an activator of Cdc42, Rac1, and RhoA. J Biol Chem 275: 10141-10149, 2000.
2. Anderson RD, Haskell RE, Xia H, Roessler BJ, Davidson BL. A simple method for the rapid generation of recombinant adenovirus vectors. Gene Ther 7: 1034-1038, 2000.
3. Angers-Loustau A, Cote JF, Charest A, Dowbenko D, Spencer S, Lasky LA, Tremblay ML. Protein tyrosine phosphatase-PEST regulates focal adhesion disassembly, migration, and cytokinesis in fibroblasts. J Cell Biol 144: 1019-1031, 1999.
4. Aoto H, Sasaki H, Ishino M, Sasaki T. Nuclear translocation of cell adhesion kinase beta/proline-rich tyrosine kinase 2. Cell Struct Funct 27: 47-61, 2002.
5. Atfi A, Drobetsky E, Boissonneault M, Chapdelaine A, Chevalier S. Transforming growth factor beta down-regulates Src family protein tyrosine kinase signaling pathways. J Biol Chem 269: 30688-30693, 1994.
6. Avraham H, Park SY, Schinkmann K, Avraham S. RAFTK/Pyk2-mediated cellular signalling. Cell Signal 12: 123-133, 2000.
7. Brown MC, Turner CE. Paxillin: adapting to change. Physiol Rev 84: 1315-1339, 2004.
8. Burridge K, Doughman R. Front and back by Rho and Rac. Nat Cell Biol 8: 781-782, 2006.
9. Burridge K, Sastry SK, Sallee JL. Regulation of cell adhesion by protein-tyrosine phosphatases. I. Cell-matrix adhesion. J Biol Chem 281: 15593-15596, 2006.
10. Castoria G, Lombardi M, Barone MV, Bilancio A, Di DM, De FA, Varricchio L, Bottero D, Nanayakkara M, Migliaccio A, Auricchio F. Rapid signalling pathway activation by androgens in epithelial and stromal cells. Steroids 69: 517-522, 2004.
11. Cooper CR, Chay CH, Pienta KJ. The role of alpha(v)beta(3) in prostate cancer progression. Neoplasia 4: 191-194, 2002.
12. Daaka Y. Mitogenic action of LPA in prostate. Biochim Biophys Acta 1582: 265-269, 2002.
13. Davidson D, Veillette A. PTP-PEST, a scaffold protein tyrosine phosphatase, negatively regulates lymphocyte activation by targeting a unique set of substrates. EMBO J 20: 3414-3426, 2001.
14. de Amicis F, Lanzino M, Kisslinger A, Cali G, Chieffi P, Ando S, Mancini FP, Tramontano D. Loss of proline-rich tyrosine kinase 2 function induces spreading and motility of epithelial prostate cells. J Cell Physiol 209: 74-80, 2006.
15. Dermardirossian C, Rocklin G, Seo JY, Bokoch GM. Phosphorylation of RhoGDI by Src regulates Rho GTPase binding and cytosol-membrane cycling. Mol Biol Cell 17: 4760-4768, 2006.
16. Dikic I, Tokiwa G, Lev S, Courtneidge SA, Schlessinger J. A role for Pyk2 and Src in linking G-protein-coupled receptors with MAP kinase activation. Nature 383: 547-550, 1996.
17. Dovas A, Couchman JR. RhoGDI: multiple functions in the regulation of Rho family GTPase activities. Biochem J 390: 1-9, 2005.
18. Duong L, Lakkakorpi P, Nakamura I, Rodan GA. Integrins and signaling in osteoclast function. Matrix Biol 19: 97-105, 2000.
19. Duong LT, Lakkakorpi PT, Nakamura I, Machwate M, Nagy RM, Rodan GA. PYK2 in osteoclasts is an adhesion kinase, localized in the sealing zone, activated by ligation of alpha(v)beta3 integrin, and phosphorylated by src kinase. J Clin Invest 102: 881-892, 1998.
20. Edlund S, Landstrom M, Heldin CH, Aspenstrom P. Transforming growth factor-beta-induced mobilization of actin cytoskeleton requires signaling by small GTPases Cdc42 and RhoA. Mol Biol Cell 13: 902-914, 2002.
21. Evangelou A, Letarte M, Marks A, Brown TJ. Androgen modulation of adhesion and antiadhesion molecules in PC-3 prostate cancer cells expressing androgen receptor. Endocrinology 143: 3897-3904, 2002.
22. Fan S, Gao M, Meng Q, Laterra JJ, Symons MH, Coniglio S, Pestell RG, Goldberg ID, Rosen EM. Role of NF-kappaB signaling in hepatocyte growth factor/scatter factor-mediated cell protection. Oncogene 24: 1749-1766, 2005.
23. Ganju RK, Hatch WC, Avraham H, Ona MA, Druker B, Avraham S, Groopman JE. RAFTK, a novel member of the focal adhesion kinase family, is phosphorylated and associates with signaling molecules upon activation of mature T lymphocytes. J Exp Med 185: 1055-1063, 1997.
24. Greenberg DL, Mize GJ, Takayama TK. Protease-activated receptor mediated RhoA signaling and cytoskeletal reorganization in LNCaP cells. Biochemistry 42: 702-709, 2003.
25. Gupta A, Lee BS, Khadeer MA, Tang Z, Chellaiah M, Abu-Amer Y, Goldknopf J, Hruska KA. Leupaxin is a critical adaptor protein in the adhesion zone of the osteoclast. J Bone Miner Res 18: 669-685, 2003.
26. Hauck CR, Klingbeil CK, Schlaepfer DD. Focal adhesion kinase functions as a receptor-proximal signaling component required for directed cell migration. Immunol Res 21: 293-303, 2000.
27. Heitzer MD, DeFranco DB. Hic-5/ARA55, a LIM domain-containing nuclear receptor coactivator expressed in prostate stromal cells. Cancer Res 66: 7326-7333, 2006.
28. Henley JM, Nishimune A. CAKbeta/Pyk2 activates Src: another piece in the puzzle of LTP induction. Neuron 29: 312-314, 2001.
29. Heo J, Thapar R, Campbell SL. Recognition and activation of Rho GTPases by Vav1 and Vav2 guanine nucleotide exchange factors. Biochemistry 44: 6573-6585, 2005.
30. Hodge JC, Bub J, Kaul S, Kajdacsy-Balla A, Lindholm PF. Requirement of RhoA activity for increased nuclear factor kappaB activity and PC-3 human prostate cancer cell invasion. Cancer Res 63: 1359-1364, 2003.
31. Hornstein I, Alcover A, Katzav S. Vav proteins, masters of the world of cytoskeleton organization. Cell Signal 16: 1-11, 2004.
32. Hwang YS, Hodge JC, Sivapurapu N, Lindholm PF. Lysophosphatidic acid stimulates PC-3 prostate cancer cell Matrigel invasion through activation of RhoA and NF-kappaB activity. Mol Carcinog 45: 518-529, 2006.
33. Jamieson JS, Tumbarello DA, Halle M, Brown MC, Tremblay ML, Turner CE. Paxillin is essential for PTP-PEST-dependent regulation of cell spreading and motility: a role for paxillin kinase linker. J Cell Sci 118: 5835-5847, 2005.
34. Kasai M, Guerrero-Santoro J, Friedman R, Leman ES, Getzenberg RH, DeFranco DB. The Group 3 LIM domain protein paxillin potentiates androgen receptor transactivation in prostate cancer cell lines. Cancer Res 63: 4927-4935, 2003.
35. Khadeer MA, Sahu SN, Bai G, Abdulla S, Gupta A. Expression of the zinc transporter ZIP1 in osteoclasts. Bone 37: 296-304, 2005.
36. Kim-Kaneyama J, Shibanuma M, Nose K. Transcriptional activation of the c-fos gene by a LIM protein, Hic-5. Biochem Biophys Res Commun 299: 360-365, 2002.
37. Knight-Krajewski S, Welsh CF, Liu Y, Lyons LS, Faysal JM, Yang ES, Burnstein KL. Deregulation of the Rho GTPase, Rac1, suppresses cyclin-dependent kinase inhibitor p21(CIP1) levels in androgen-independent human prostate cancer cells. Oncogene 23: 5513-5522, 2004.
38. Lecrone V, Li W, Devoll RE, Logothetis C, Farach-Carson MC. Calcium signals in prostate cancer cells: specific activation by bone-matrix proteins. Cell Calcium 27: 35-42, 2000.
39. Lee LF, Louie MC, Desai SJ, Yang J, Chen HW, Evans CP, Kung HJ. Interleukin-8 confers androgen-independent growth and migration of LNCaP: differential effects of tyrosine kinases Src and FAK. Oncogene 23: 2197-2205, 2004.
40. Lipsky BP, Beals CR, Staunton DE. Leupaxin is a novel LIM domain protein that forms a complex with PYK2. J Biol Chem 273: 11709-11713, 1998.
41. Lyons PD, Dunty JM, Schaefer EM, Schaller MD. Inhibition of the catalytic activity of cell adhesion kinase beta by protein-tyrosine phosphatase-PEST-mediated dephosphorylation. J Biol Chem 276: 24422-24431, 2001.
42. Migliaccio A, Castoria G, Di DM, De FA, Bilancio A, Lombardi M, Bottero D, Varricchio L, Nanayakkara M, Rotondi A, Auricchio F. Sex steroid hormones act as growth factors. J Steroid Biochem Mol Biol 83: 31-35, 2002.
43. Nam S, Kim D, Cheng JQ, Zhang S, Lee JH, Buettner R, Mirosevich J, Lee FY, Jove R. Action of the Src family kinase inhibitor, dasatinib (BMS-354825), on human prostate cancer cells. Cancer Res 65: 9185-9189, 2005.
44. Okigaki M, Davis C, Falasca M, Harroch S, Felsenfeld DP, Sheetz MP, Schlessinger J. Pyk2 regulates multiple signaling events crucial for macrophage morphology and migration. Proc Natl Acad Sci USA 100: 10740-10745, 2003.
45. Park SY, Schinkmann KA, Avraham S. RAFTK/Pyk2 mediates LPA-induced PC12 cell migration. Cell Signal 18: 1063-1071, 2006.
46. Picascia A, Stanzione R, Chieffi P, Kisslinger A, Dikic I, Tramontano D. Proline-rich tyrosine kinase 2 regulates proliferation and differentiation of prostate cells. Mol Cell Endocrinol 186: 81-87, 2002.
47. Playford MP, Schaller MD. The interplay between Src and integrins in normal and tumor biology. Oncogene 23: 7928-7946, 2004.
48. Recchia I, Rucci N, Festuccia C, Bologna M, Mackay AR, Migliaccio S, Longo M, Susa M, Fabbro D, Teti A. Pyrrolopyrimidine c-Src inhibitors reduce growth, adhesion, motility and invasion of prostate cancer cells in vitro. Eur J Cancer 39: 1927-1935, 2003.
49. Rhodes DR, Barrette TR, Rubin MA, Ghosh D, Chinnaiyan AM. Meta-analysis of microarrays: interstudy validation of gene expression profiles reveals pathway dysregulation in prostate cancer. Cancer Res 62: 4427-4433, 2002.
50. Russell PJ, Bennett S, Stricker P. Growth factor involvement in progression of prostate cancer. Clin Chem 44: 705-723, 1998.
51. Sahu SN, Khadeer MA, Robertson BW, Nunez S, Bai G, Gupta A. Association of leupaxin with Src in osteoclasts. Am J Physiol Cell Physiol 292: C581-C590, 2007.
52. Sastry SK, Lyons PD, Schaller MD, Burridge K. PTP-PEST controls motility through regulation of Rac1. J Cell Sci 115: 4305-4316, 2002.
53. Sastry SK, Rajfur Z, Liu BP, Cote JF, Tremblay M, Burridge K. PTP-PEST couples membrane protrusion and tail retraction via VAV2 and p190RhoGAP. J Biol Chem 281: 11627-11636, 2006.
54. Schaller MD. Paxillin: a focal adhesion-associated adaptor protein. Oncogene 20: 6459-6472, 2001.
55. Shen Y, Lyons P, Cooley M, Davidson D, Veillette A, Salgia R, Griffin JD, Schaller MD. The noncatalytic domain of protein-tyrosine phosphatase-PEST targets paxillin for dephosphorylation in vivo. J Biol Chem 275: 1405-1413, 2000.
56. Shen Y, Schneider G, Cloutier JF, Veillette A, Schaller MD. Direct association of protein-tyrosine phosphatase PTP-PEST with paxillin. J Biol Chem 273: 6474-6481, 1998.
57. Shevrin DH, Kukreja SC, Ghosh L, Lad TE. Development of skeletal metastasis by human prostate cancer in athymic nude mice. Clin Exp Metastasis 6: 401-409, 1988.
58. Shibanuma M, Ishino K, Sakamoto N, Nose K. Accumulation of focal adhesion protein hic-5 in the nucleus by hydrogen peroxide. Acta Histochem Cytochem 34: 259-264, 2001.
59. Sieg DJ, Hauck CR, Ilic D, Klingbeil CK, Schaefer E, Damsky CH, Schlaepfer DD. FAK integrates growth-factor and integrin signals to promote cell migration. Nat Cell Biol 2: 249-256, 2000.
60. Slack JK, Adams RB, Rovin JD, Bissonette EA, Stoker CE, Parsons JT. Alterations in the focal adhesion kinase/Src signal transduction pathway correlate with increased migratory capacity of prostate carcinoma cells. Oncogene 20: 1152-1163, 2001.
61. Somlyo AV, Bradshaw D, Ramos S, Murphy C, Myers CE, Somlyo AP. Rho-kinase inhibitor retards migration and in vivo dissemination of human prostate cancer cells. Biochem Biophys Res Commun 269: 652-659, 2000.
62. Stanzione R, Picascia A, Chieffi P, Imbimbo C, Palmieri A, Mirone V, Staibano S, Franco R, De Rosa G, Schlessinger J, Tramontano D. Variations of proline-rich kinase Pyk2 expression correlate with prostate cancer progression. Lab Invest 81: 51-59, 2001.
63. Stearns ME. Alendronate blocks TGF-beta1 stimulated collagen 1 degradation by human prostate PC-3 ML cells. Clin Exp Metastasis 16: 332-339, 1998.
64. Susa M, Glatt M, Teti A. Tumor bone diseases: molecular mechanisms and opportunities for novel treatments. Curr Med Chem Anticancer Agents 1: 313-329, 2001.
65. Tang Z, Sahu SN, Khadeer MA, Bai G, Franklin RB, Gupta A. Overexpression of the ZIP1 zinc transporter induces an osteogenic phenotype in mesenchymal stem cells. Bone 38: 181-198, 2006.
66. Tremblay L, Hauck W, Nguyen LT, Allard P, Landry F, Chapdelaine A, Chevalier S. Regulation and activation of focal adhesion kinase and paxillin during the adhesion, proliferation, and differentiation of prostatic epithelial cells in vitro and in vivo. Mol Endocrinol 10: 1010-1020, 1996.
67. Turner CE. Paxillin. Int J Biochem Cell Biol 30: 955-959, 1998.
68. Turner CE. Paxillin interactions. J Cell Sci 113: 4139-4140, 2000.
69. Turner CE, Miller JT. Primary sequence of paxillin contains putative SH2 and SH3 domain binding motifs and multiple LIM domains: identification of a vinculin and pp125Fak-binding region. J Cell Sci 107: 1583-1591, 1994.
70. Wade R, Bohl J, Vande PS. Paxillin null embryonic stem cells are impaired in cell spreading and tyrosine phosphorylation of focal adhesion kinase. Oncogene 21: 96-107, 2002.
71. Wang X, Yang Y, Guo X, Sampson ER, Hsu CL, Tsai MY, Yeh S, Wu G, Guo Y, Chang C. Suppression of androgen receptor transactivation by Pyk2 via interaction and phosphorylation of the ARA55 coregulator. J Biol Chem 277: 15426-15431, 2002.
72. Watanabe N, Amano N, Ishizuka H, Mashima K. Leupaxin binds to PEST domain tyrosine phosphatase PEP. Mol Cell Biochem 269: 13-17, 2005.
73. Wells CM, Ahmed T, Masters JR, Jones GE. Rho family GTPases are activated during HGF-stimulated prostate cancer-cell scattering. Cell Motil Cytoskeleton 62: 180-194, 2005.
74. West KA, Zhang H, Brown MC, Nikolopoulos SN, Riedy MC, Horwitz AF, Turner CE. The LD4 motif of paxillin regulates cell spreading and motility through an interaction with paxillin kinase linker (PKL). J Cell Biol 154: 161-176, 2001.
75. Woods AJ, Roberts MS, Choudhary J, Barry ST, Mazaki Y, Sabe H, Morley SJ, Critchley DR, Norman JC. Paxillin associates with poly(A)-binding protein 1 at the dense endoplasmic reticulum and the leading edge of migrating cells. J Biol Chem 277: 6428-6437, 2002.
76. Xiong WC, Feng X. PYK2 and FAK in osteoclasts. Front Biosci 8: d1219-d1226, 2003.
77. Yao H, Dashner EJ, van Golen CM, van Golen KL. RhoC GTPase is required for PC-3 prostate cancer cell invasion but not motility. Oncogene 25: 2285-2296, 2006.
78. Zalcman G, Dorseuil O, Garcia-Ranea JA, Gacon G, Camonis J. RhoGAPs and RhoGDIs, (His)stories of two families. Prog Mol Subcell Biol 22: 85-113, 1999.
79. Zheng DQ, Woodard AS, Fornaro M, Tallini G, Languino LR. Prostatic carcinoma cell migration via alpha(v)beta3 integrin is modulated by a focal adhesion kinase pathway. Cancer Res 59: 1655-1664, 1999.
80. Zheng DQ, Woodard AS, Tallini G, Languino LR. Substrate specificity of alpha(v)beta(3) integrin-mediated cell migration and phosphatidylinositol 3-kinase/AKT pathway activation. J Biol Chem 275: 24565-24574, 2000.
81. Zhou J, Scholes J, Hsieh JT. Characterization of a novel negative regulator (DOC-2/DAB2) of c-Src in normal prostatic epithelium and cancer. J Biol Chem 278: 6936-6941, 2003.
82. Zrihan-Licht S, Avraham S, Jiang S, Fu Y, Avraham HK. Coupling of RAFTK/Pyk2 kinase with c-Abl and their role in the migration of breast cancer cells. Int J Oncol 24: 153-159, 2004.